Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
This study has been completed.
Study NCT00067730   Information provided by Eli Lilly and Company
First Received: August 25, 2003   Last Updated: December 3, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sepsis
Hematologic Neoplasms
Infection
Additional conditions recognized in this trial
Communicable Diseases
Neoplasms
More general conditions related to this trial
Hematologic Diseases
Inflammation
Neoplasms by Site
Pathologic Processes
Systemic Inflammatory Response Syndrome
Interventions listed in this trial
Drotrecogin Alfa (activated)
Additional drug interventions recognized in this trial
Drotrecogin alfa activated
Protein C
More general drug interventions related to this trial
Anti-Infective Agents
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services